W. R. Berkley
WRB
$75.92
+0.92%
W.R. Berkley Corporation is an insurance holding company whose subsidiaries primarily underwrite commercial casualty insurance, specializing in niche excess and surplus lines, workers' compensation, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses. Unlike broad-based carriers, Berkley operates as a decentralized collection of specialized underwriting units, giving it a distinct identity as a disciplined, cycle-aware niche underwriter rather than a scale-driven commodity insurer. The current investor narrative centers on whether the company can sustain underwriting margins as commercial P&C pricing decelerates, with recent quarterly results showing flat-to-slightly-negative revenue growth and a modest year-over-year decline in net income. Analyst sentiment has turned cautious, with several firms reiterating Neutral or Underweight stances, reflecting debate over premium growth durability and reserve adequacy in a softening rate environment.…
WRB
W. R. Berkley
$75.92
Related headlines
Investment Opinion: Should I buy WRB Today?
Rating: Hold. The core thesis is that W.R. Berkley is a high-quality niche commercial casualty underwriter (18.34% ROE, 0.29 debt-to-equity, $3.10 billion trailing FCF) whose stock has simply outrun its fundamentals — at $75.23 it trades roughly 8.0% above the $69.18 analyst average target, with a consensus recommendation of Hold (mean 3.39) built on 2 Buy, 9 Hold, and 7 Sell ratings. The quality is real, but the price already reflects it, and the near-term risk/reward is skewed modestly negative.
Supporting evidence is mixed but tilts toward patience rather than accumulation. Valuation is full: 15.65x trailing and 15.50x forward earnings with a PEG of 7.63 and 2.87x book near the top of its 2.3x-3.2x four-year band. Growth has stalled — Q3 2026 revenue of $3.739 billion fell 0.77% YoY and net income dropped 12.7% to $446.0 million, compressing net margin from 13.6% to 11.9% and EPS from $1.29 to $1.15. The offsetting strengths are balance-sheet and cash-flow quality: $3.10 billion trailing FCF, $721 million of quarterly FCF, a 1.39 current ratio, an 18.34% ROE, and a 2.52% dividend yield at a conservative 39.4% payout ratio. Momentum is the one genuinely bullish input — +7.89% in one month and +14.54% over six months, beating SPY by 12.88 and 15.08 points respectively — but momentum alone at a premium to consensus fair value is a thin margin of safety.
Three risks could invalidate even a Hold: continued commercial P&C rate softening compressing underwriting margins further (already visible in the 15.7% Q4 2024 net margin falling to 11.9%), adverse casualty reserve development forcing charges, and multiple de-rating toward the low end of the 12.6x-18.2x recent PE band. The rating would upgrade to Buy if the stock pulled back toward the $62.87 52-week low (roughly -16%) while ROE held above 18% and premium pricing stabilized, or if forward EPS estimates rose above the $5.34 high end on firming rates. It would downgrade to Sell if revenue growth turned negative beyond -3% or if net margin fell below 10%. Verdict: fairly valued to modestly overvalued relative to consensus and its own recent history — a quality compounder worth owning on weakness, not at a premium to analyst fair value.
Sign up to view all
WRB 12-Month Price Forecast
The forward view is genuinely balanced: W.R. Berkley is a quality underwriter with an 18.34% ROE, negligible leverage at 0.29 debt-to-equity, and $3.10 billion of trailing free cash flow, but the stock at $75.23 has already priced that quality in, sitting 8.0% above the $69.18 consensus target with a PEG of 7.63 and flat revenue growth of -0.77%. The 55% base case assumes premium growth stays near the $3.7 billion quarterly run-rate and EPS lands near the $5.09 consensus, pulling the price back toward the high-$60s to low-$70s. The 20% bull case requires commercial casualty pricing to firm and margins to recover, while the 25% bear case reflects the real risk of adverse reserve development and a de-rating toward the $62.87 52-week low or the $51.00 analyst low. I would upgrade to bullish if the stock pulled back toward $65 while ROE held above 18% and net margin stabilized above 13%, and downgrade to bearish if net margin broke below 10% or revenue growth fell past -3%.
Wall Street consensus
Coverage is broad with 17 analysts, but sentiment is decidedly cautious: 2 Buy, 9 Hold, and 7 Sell ratings produce a consensus recommendation of Hold and a recommendation mean of 3.39 (where higher numbers skew bearish). The average target price of $69.18 implies roughly -8.0% downside from the current $75.23, meaning the stock is trading above consensus fair value — an unusual and important signal that the recent rally has outrun analyst models. The consensus clearly leans neutral-to-bearish, and the estimated EPS average of $5.09 (range $4.96 to $5.34) against a $75.23 price implies a forward PE of about 14.8x, consistent with the reported 15.50x forward multiple. The target range is wide, from $51.00 to $83.00 — a 63% spread from low to high — which signals genuine disagreement about the earnings trajectory. The high target of $83.00 (about +10.3% upside) would require multiple expansion toward 16-17x forward earnings and a stabilization or reacceleration of premium growth, likely contingent on firming commercial P&C pricing or better-than-expected investment income. The low target of $51.00 (about -32% downside) prices in margin compression from a softening rate cycle, adverse reserve development, or a broader recession hitting commercial exposures. Institutional ratings show a consistent pattern of reiterations rather than upgrades: Wells Fargo has maintained Underweight (most recently October 20, 2026), Evercore ISI has stayed at Underperform, and Morgan Stanley, Mizuho, UBS, and Cantor Fitzgerald have all reiterated Neutral or Equal Weight through October 2026 — no firm has upgraded the name recently. That uniformity of caution, combined with the stock trading above the average target, suggests limited near-term catalyst support and elevated risk of mean reversion toward the consensus level.
Bulls vs Bears: WRB Investment Factors
The bear case currently holds slightly stronger near-term evidence: the stock trades 8.0% above the $69.18 analyst average target, revenue is flat at -0.77% YoY, net margin has compressed from 13.6% to 11.9%, and 16 of 17 analysts rate it Hold or Sell with no recent upgrades. The bull case rests on quality and momentum rather than growth — an 18.34% ROE, 0.29 debt-to-equity, $3.10 billion in trailing FCF, and 15.08 points of six-month relative strength versus SPY — which explains why the stock has rallied despite cautious fundamentals. The single most important tension is whether commercial P&C pricing stabilizes before underwriting margins compress further; if premium rates firm, the 15.5x forward multiple and 2.87x book look justified, but continued rate softening would validate the bears' mean-reversion thesis toward the low-$60s. The wide $51-$83 target range (63% spread) confirms genuine disagreement about this earnings trajectory, making the next few quarters of pricing data the decisive variable.
Bullish
- Strong relative momentum vs. market: WRB has outperformed the S&P 500 by 12.88 percentage points over the past month and 15.08 points over six months, even as SPY fell 4.99% and 0.54% respectively. The stock is up 7.89% in one month and 14.54% over six months, a sharp reversal from its flat 0.87% one-year return, suggesting a genuine trend reversal rather than a dead-cat bounce.
- Pristine balance sheet and cash generation: Debt-to-equity is just 0.29 and the current ratio is 1.39, while trailing free cash flow reached $3.10 billion with quarterly FCF of $721 million in Q3 2026. Cash of $2.11 billion comfortably covers the $259.8 million quarterly dividend and modest buybacks, leaving room for continued capital return without external financing.
- High ROE justifies book premium: ROE of 18.34% is excellent for the P&C sector and well above the company's own quarterly period readings of 4.6-5.3%. This profitability supports the 2.87x price-to-book, which sits within the historical 2.3x-3.2x band and reflects quality underwriting rather than speculative excess.
- Defensive low-beta profile: A beta of just 0.221 makes WRB roughly 78% less volatile than the market, providing meaningful downside protection in selloffs. The 2.52% dividend yield with a conservative 39.4% payout ratio adds a reliable income component to total return.
Bearish
- Trading above analyst fair value: The average analyst target of $69.18 implies roughly -8.0% downside from the current $75.23, an unusual signal that the recent rally has outrun consensus models. With 7 Sell ratings versus only 2 Buy ratings and a recommendation mean of 3.39, sentiment is decidedly cautious.
- Revenue growth has stalled: Q3 2026 revenue of $3.739 billion was down 0.77% year over year versus $3.768 billion in Q3 2025, and the multi-quarter trend shows a plateau around $3.7 billion per quarter. Flat revenue in a P&C insurer signals premium-rate deceleration outpacing exposure growth, capping the top-line investment case.
- Margin and earnings compression: Q3 2026 net income fell to $446.0 million at an 11.9% net margin, down from $511.0 million and 13.6% in Q3 2025, with EPS slipping to $1.15 from $1.29. The decline from the Q4 2024 peak of $576.1 million at a 15.7% margin reflects softer underwriting and a higher 21.9% effective tax rate.
- PEG of 7.63 flags expensive growth: The PEG ratio of 7.63 signals the current 15.65x trailing PE is expensive relative to the company's growth rate, which is the core valuation debate for this name. The narrow gap between trailing (15.65x) and forward (15.50x) multiples implies the market expects essentially flat earnings growth.
WRB Technical Analysis
WRB is in a recovery uptrend that has stalled just below its highs: the stock is up 0.87% over the past year but sits at $75.23, roughly 85.6% of its 52-week range of $62.87 to $79.26, meaning it trades about $4 below the high and $12.36 above the low. That positioning signals momentum that is constructive but not overextended, with the stock having reclaimed most of the ground lost during a drawdown that reached -19.02% at its worst. The 180-day price series confirms a choppy base between roughly $63.50 and $76.98 before the recent push toward the upper end of the range. Short-term momentum is clearly accelerating: the stock is up 7.89% over the past month and 5.07% over three months, a sharp reversal from the flat 0.87% one-year return, and the 14.54% six-month gain shows the recovery has been building since spring. This divergence between weak trailing annual performance and strong recent gains suggests a trend reversal rather than a dead-cat bounce, and the relative strength versus SPY is striking — WRB outperformed the S&P 500 by 12.88 percentage points over one month and 15.08 points over six months, even as SPY fell 4.99% and 0.54% respectively over those windows. The lone caveat is the most recent session, which saw a -2.27% pullback from $76.98 to $75.23 on volume of about 1.85 million shares, a normal pause after a strong run. Key resistance sits at the 52-week high of $79.26; a clean breakout above that level would confirm the recovery and open the door to new highs, while support rests at the 52-week low of $62.87, with intermediate support likely around the $70-72 area that contained the stock through August and September. The stock's beta of just 0.221 is a critical risk-management input: WRB is roughly 78% less volatile than the market, so it behaves defensively in selloffs but also lags in broad rallies, making it better suited to lower-beta, income-oriented allocations than to momentum-driven position sizing. The short ratio of 0.01 indicates negligible short interest, removing squeeze dynamics but also confirming there is little bearish conviction betting against the name.
Beta
—
—
Max Drawdown
-19.0%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+1.3%
Cumulative gain past year
| Period | WRB Return | S&P 500 |
|---|---|---|
| 1m | +5.6% | -3.3% |
| 3m | +8.3% | -2.3% |
| 6m | +16.0% | +1.4% |
| 1y | +1.3% | +12.2% |
| ytd | +9.5% | +10.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRB Fundamental Analysis
Revenue growth has essentially stalled: Q3 2026 revenue of $3.739 billion was down 0.77% year over year versus $3.768 billion in Q3 2025, and the multi-quarter trend shows a plateau — $3.688 billion in Q1 2026, $3.731 billion in Q4 2025, and $3.671 billion in Q2 2025 — with no meaningful sequential expansion. The Q2 2026 figure of $6.831 billion is a reporting artifact from gross-versus-net presentation and should not be read as a doubling of the business; the underlying run-rate is roughly $3.7 billion per quarter. The only disclosed segment, Reinsurance-Global, contributed $426.6 million, a modest slice of the total, so the bulk of revenue remains concentrated in commercial casualty lines where pricing has softened. Flat revenue in a P&C insurer typically signals premium-rate deceleration outpacing exposure growth, which caps the top-line investment case and shifts the burden of earnings growth onto underwriting discipline and investment income. Profitability remains solid but is compressing: Q3 2026 net income was $446.0 million with a net margin of 11.9%, down from $511.0 million and a 13.6% margin in Q3 2025, and EPS slipped to $1.15 from $1.29. The quarterly net margin path — 13.97% in Q1 2026, 6.62% in Q2 (distorted by the gross presentation), 11.93% in Q3, and 12.09% in Q4 2025 — shows the underlying margin settling in the low-to-mid teens, while the operating margin of 15.87% and combined-ratio proxy (EBIT margin of 16.21% in Q3) remain healthy for a commercial casualty underwriter. The reported gross margin of 19.81% is not meaningful for an insurer and should be disregarded in favor of the net and operating margins. The compression from the 2024 peak — Q4 2024 net income was $576.1 million at a 15.7% margin — reflects both softer underwriting results and a higher tax rate, with the effective tax rate at 21.9% in Q3 2026. Balance sheet and cash generation are strong: debt-to-equity is just 0.29, the current ratio is 1.39, and trailing free cash flow is $3.10 billion, with quarterly FCF of $721 million in Q3 2026, $812 million in Q2, and $668 million in Q1. ROE of 18.34% is excellent for the sector and well above the company's own quarterly ratio readings (which show 4.6-5.3% on a period basis), while ROA of 3.43% is consistent with a leveraged insurer. Cash of $2.11 billion at quarter-end comfortably covers the $259.8 million quarterly dividend and $21.1 million of buybacks, and the 2.52% dividend yield with a 39.4% payout ratio leaves ample room for both continued capital return and internal growth funding without external financing.
Quarterly Revenue
$3.7B
2026-09
Revenue YoY Growth
-0.8%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRB Overvalued?
Because net income is positive ($446.0 million in Q3 2026), the PE ratio is the appropriate primary metric. WRB trades at 15.65x trailing earnings and 15.50x forward earnings, a remarkably narrow gap that implies the market expects essentially flat earnings growth — consistent with the -0.77% revenue decline and the modest EPS trajectory from $1.15 to an estimated $5.09 annualized. The PEG ratio of 7.63 is the red flag here: it signals that the current multiple is expensive relative to the company's growth rate, which is the core valuation debate for this name. Against the P&C insurance industry, a 15.65x PE is roughly in line with the sector's typical high-teens multiple, so WRB is not trading at a dramatic premium, but its 2.87x price-to-book is rich for an insurer earning an 18.3% ROE — the market is paying up for quality underwriting and balance-sheet strength rather than for growth. The 1.89x price-to-sales and 1.94x EV-to-sales are moderate, while the 11.85x EV/EBITDA is reasonable for a cash-generative financial. The premium to book is arguably justified by the 18.34% ROE and 0.29 debt-to-equity, but the 7.63 PEG suggests the market has already priced in the quality. Historically, WRB's PE has ranged from about 7.8x (Q1 2022) to 26.5x (Q2 2022), with the more recent band settling between roughly 12.6x and 18.2x over the past two years; the current 15.65x sits in the middle-to-upper portion of that recent range, not at an extreme. The price-to-book of 2.87x compares with a historical band of roughly 2.3x to 3.2x over the past four years, placing it near the upper end — the market is pricing in optimistic but not euphoric expectations. The takeaway is a fairly valued quality compounder: neither a deep-value opportunity nor an overextended momentum name, with the 2.52% dividend yield providing a meaningful component of total return.
PE
15.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 10x~18x
vs. Industry Avg
12.7x
Industry PE ~12.7x*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings erosion rather than balance-sheet stress. Net income fell from $511.0 million in Q3 2025 to $446.0 million in Q3 2026, a 12.7% decline, while net margin compressed from 13.6% to 11.9% and EPS slipped from $1.29 to $1.15. Revenue is effectively frozen at roughly $3.7 billion per quarter with -0.77% YoY growth, meaning any further underwriting deterioration flows directly to the bottom line with no top-line buffer, and the bulk of revenue is concentrated in commercial casualty lines where pricing has softened. Reserve adequacy is the key operational wildcard — adverse development in long-tail casualty lines could force charges that overwhelm the otherwise strong 0.29 debt-to-equity and $3.10 billion trailing FCF position.
Market and competitive risks are dominated by valuation compression and cycle sensitivity. At 15.65x trailing and 15.50x forward earnings with a 7.63 PEG, the market has already priced in quality, and the stock trading 8.0% above the $69.18 consensus target creates mechanical mean-reversion pressure as analysts defend their models. The 2.87x price-to-book sits near the upper end of its four-year 2.3x-3.2x band, leaving little cushion if ROE slips below the current 18.34%. A beta of just 0.221 limits macro-driven drawdowns but also means WRB lags in broad rallies, and sector rotation away from financials — reinforced by the uniform Underweight/Underperform/Neutral reiterations from Wells Fargo, Evercore ISI, Morgan Stanley, Mizuho, UBS, and Cantor Fitzgerald — offers no offsetting catalyst.
The worst-case scenario is a compounding of softening commercial P&C rates, adverse reserve development in casualty lines, and a recession hitting commercial exposures simultaneously. In that chain, underwriting margins compress toward mid-single digits, EPS undershoots the $5.09 consensus, and the multiple de-rates toward the low end of its 12.6x-18.2x recent band, driving the stock toward the $51.00 analyst low target — roughly -32% from $75.23. A less severe but still painful outcome is reversion to the 52-week low of $62.87, about -16.4% from the current price, consistent with the -19.02% max drawdown already experienced. The $51 bear target and the $62.87 52-week low bracket a realistic downside range of -16% to -32% if the rate cycle turns decisively against the company.
FAQ
Ranked by severity: first, earnings and margin compression — Q3 2026 net income fell 12.7% to $446.0 million with net margin down from 13.6% to 11.9% and EPS from $1.29 to $1.15, and with revenue frozen near $3.7 billion per quarter there is no top-line buffer. Second, reserve adequacy in long-tail casualty lines, where adverse prior-year development could force charges that overwhelm the otherwise strong 0.29 debt-to-equity and $3.10 billion FCF position. Third, valuation de-rating — at 15.50x forward with a 7.63 PEG and 2.87x book near its band top, a slip in ROE below 18.34% or continued P&C rate softening could pull the multiple toward the low end of 12.6x-18.2x. Fourth, macro and cycle sensitivity: a recession would raise commercial claims frequency across small and midsize business exposures, and while the 0.221 beta limits market-driven drawdowns, it also means WRB lags in rallies and offers no offset to sector rotation away from financials.
The 12-month view splits into three scenarios. The base case (55% probability, $66-$72) assumes premium growth stays near the $3.7 billion quarterly run-rate, net margin stabilizes in the low-to-mid teens, and EPS lands near the $5.09 consensus, pulling the price from $75.23 back toward the $69.18 analyst average. The bear case (25%, $51-$62.87) assumes a softening commercial P&C cycle plus adverse casualty reserve development and a recession, driving EPS below the $4.96 low estimate and the stock to the 52-week low or the $51.00 analyst low — a -16% to -32% move. The bull case (20%, $79.26-$83.00) requires casualty and E&S pricing to firm, net margin to recover above 13%, and the multiple to expand to 16-17x forward, carrying the stock through the $79.26 52-week high to the $83.00 high target. The base case is most likely, and its key assumption is that margins hold rather than re-test the 15.7% Q4 2024 peak.
WRB looks fairly valued to modestly overvalued. It trades at 15.65x trailing and 15.50x forward earnings — a narrow gap implying the market expects essentially flat earnings growth, consistent with the -0.77% revenue decline — and the 7.63 PEG flags that multiple as expensive relative to the company's growth rate. On book value, 2.87x sits near the upper end of the four-year 2.3x-3.2x band, and the 15.65x PE is in the middle-to-upper portion of the recent 12.6x-18.2x range, so this is not a distressed or discounted price. The premium to book is defensible given an 18.34% ROE and negligible leverage, but the market is already paying for that quality rather than getting it cheap. The clearest valuation signal is that the stock trades above the $69.18 consensus target, implying the market expects either pricing to firm or margins to recover beyond what analysts currently model.
From a pure risk/reward standpoint the setup is only moderately attractive at $75.23: the stock sits about 8.0% above the $69.18 analyst average target, and 16 of 17 analysts rate it Hold or Sell (2 Buy, 9 Hold, 7 Sell, recommendation mean 3.39), so consensus sees limited upside from here. The quality case is genuine — 18.34% ROE, 0.29 debt-to-equity, $3.10 billion trailing FCF, and a 2.52% dividend at a conservative 39.4% payout — but the 7.63 PEG and 2.87x book near the top of the 2.3x-3.2x band mean you are paying for that quality. The biggest downside risk is a de-rating toward the $62.87 52-week low (-16.4%) or the $51.00 analyst low (-32%) if commercial P&C pricing keeps softening and margins compress further. It is a reasonable buy for patient, income-oriented investors with a 2-3 year horizon who accumulate on pullbacks toward the mid-$60s, and a poor buy for anyone chasing the recent 7.89% one-month rally at a premium to fair value.
WRB is better suited to long-term holding than short-term trading. Its 0.221 beta makes it roughly 78% less volatile than the market, which dampens the sharp swings short-term traders rely on, and the 2.52% dividend yield at a 39.4% payout ratio rewards patience with a steady income component. The business is a mature, cycle-sensitive underwriter with flat revenue (-0.77% YoY) and earnings visibility that depends on commercial P&C pricing rather than a secular growth runway, so there is no fast-compounding story to capture in a few months. The recent +14.54% six-month and +7.89% one-month gains have already pushed the stock above the $69.18 consensus target, raising near-term mean-reversion risk for anyone buying now. A suggested minimum holding period is two to three years, entered on pullbacks toward the mid-$60s, which gives time for the pricing cycle to turn and for dividends plus book-value growth to compound.